Dana-Farber Cancer Institute

Analysis

Dana-Farber Cancer Institute is a registered charity in United States, based in Boston, MA. It received its IRS tax-exemption ruling in April 1962, 64 years ago. Its declared purposes cover medical research, which this site groups under health and saving lives. The IRS classifies it as a publicly supported organisation (donations from the general public) under section 501(c)(3), and contributions to it are listed as tax-deductible.

In the financial year ending September 2023, Dana-Farber Cancer Institute reported income of $3.39bn and spending of $3.00bn, spending 89% of its income. Across the 5 years on record, from September 2019 to September 2023, income grew from $1.99bn to $3.39bn (+71%), an average of +14% a year. The sharpest change came in the year to September 2023, when income rose by 27%. Over the whole period it spent 93% of the income it received.

Among 40,470 United States charities whose main cause is health and saving lives and that reported income, Dana-Farber Cancer Institute sits at the 100th percentile: it is one of the largest 1% in its cause. Against every charity in United States with reported income it ranks in the 100th percentile, and in the 100th percentile within MA. Charities of a similar size with the same main cause include Health Share of Oregon ($3.36bn), Osf Healthcare System ($3.40bn) and Peacehealth ($3.34bn).

On its Form 990 for the period ending September 2023, revenue came from contributions and grants 22% and program service revenue 67% of the total. Compensation of current officers, directors and key employees was $9.8m (0.3% of expenses). Other salaries and wages came to $753.1m. It paid $5.5m in professional fundraising fees. At year end it held assets of $4.74bn against liabilities of $1.37bn, net assets of $3.36bn. It reported 8,690 employees.